Liraglutide
Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: SCALE™ - Obesity and Pre-diabetes
Novo Nordisk · Phase 3 · Completed · Enrollment 3731
Y axis: Change in body weight from baseline, %
X axis: Weeks since randomization
Cited trial source. Only weeks the source states.
- Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68): week 56 0.69%
- Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68): week 56 2.91%
- Liraglutide Placebo, no Pre-diabetes: week 56 0.28%
One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.